Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter W Marks

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
JAMA|July 7, 2020
Identifying the Risks of Unproven Regenerative Medicine TherapiesPeter W Marks, Stephen Hahn
Current Opinion in Oncology|May 1, 2002
Medical management of patients with brain tumorsPatrick Y Wen, Peter W Marks
Science Translational Medicine|January 25, 2023
Biological therapies need definitive randomized controlled clinical trialsRobert M Califf, Peter W Marks
Transfusion|March 28, 2017
Decision making in the face of uncertainty: the challenge of emerging infectious diseasesPeter W Marks, Lyle R Petersen
Journal of General Internal Medicine|May 1, 2024
Achieving Diversity Through DecentralizationEli Y Adashi, Peter W Marks
The New England Journal of Medicine|September 24, 2004
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-2004. A 37-year-old woman with paresthesias of the arms and legsPeter W Marks, Lawrence R Zukerberg
Blood|October 9, 2010
Gemtuzumab ozogamicin: is there room for salvage?W Thomas Clarke, Peter W Marks
The New England Journal of Medicine|March 1, 2023
Bivalent Covid-19 VaccinesPeter W Marks, Robert M Califf
Neuro-Oncology|March 31, 2012
Treatment-related myelodysplasia in patients with primary brain tumorsJoachim M Baehring, Peter W Marks
American Journal of Hematology|August 4, 2009
Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemiaSaeeda Chowdhury, Stuart Seropian, Peter W Marks
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
JAMA|July 7, 2020
Identifying the Risks of Unproven Regenerative Medicine TherapiesPeter W Marks, Stephen Hahn
Current Opinion in Oncology|May 1, 2002
Medical management of patients with brain tumorsPatrick Y Wen, Peter W Marks
Science Translational Medicine|January 25, 2023
Biological therapies need definitive randomized controlled clinical trialsRobert M Califf, Peter W Marks
Transfusion|March 28, 2017
Decision making in the face of uncertainty: the challenge of emerging infectious diseasesPeter W Marks, Lyle R Petersen
Journal of General Internal Medicine|May 1, 2024
Achieving Diversity Through DecentralizationEli Y Adashi, Peter W Marks
The New England Journal of Medicine|September 24, 2004
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-2004. A 37-year-old woman with paresthesias of the arms and legsPeter W Marks, Lawrence R Zukerberg
Blood|October 9, 2010
Gemtuzumab ozogamicin: is there room for salvage?W Thomas Clarke, Peter W Marks
The New England Journal of Medicine|March 1, 2023
Bivalent Covid-19 VaccinesPeter W Marks, Robert M Califf
Neuro-Oncology|March 31, 2012
Treatment-related myelodysplasia in patients with primary brain tumorsJoachim M Baehring, Peter W Marks
American Journal of Hematology|August 4, 2009
Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemiaSaeeda Chowdhury, Stuart Seropian, Peter W Marks
Pageof 4